Primary systemic amyloidoses: possible new directions in prophylaxis and therapy.
Oken
R J
RJ
D000544:Alzheimer Disease / Q000188:drug therapy / Q000503:physiopathology / Q000517:prevention & control; D000686:Amyloidosis / Q000188:drug therapy* / Q000503:physiopathology* / Q000517:prevention & control; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use*; D003622:Dapsone / Q000627:therapeutic use; D003704:Dementia / Q000453:epidemiology / Q000209:etiology / Q000517:prevention & control; D006801:Humans; D007917:Leprostatic Agents / Q000627:therapeutic use; D007918:Leprosy / Q000150:complications / Q000188:drug therapy; D008954:Models, Biological
D000894:Anti-Inflammatory Agents, Non-Steroidal; D007917:Leprostatic Agents; D003622:Dapsone